Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 1.00 |
| ▸ | ATR | Q13535 | 8/20 | 1.00 |
| ▸ | MTOR | P42345 | 14/20 | 0.71 |
| ▸ | PRKDC | P78527 | 1/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19329262 | 1.00 | ATM (1.00) | ATMATRMTORPRKDCPIK3CA | |
| SCHEMBL19346437 | 1.00 | ATM (1.00) | ATMATRMTORPRKDCPIK3CA | |
| SCHEMBL19329277 | 0.88 | ATM (0.84) | ATMATRMTORPIK3CAKCNH2 | |
| SCHEMBL19346436 | 0.88 | ATM (0.84) | ATMATRMTORPIK3CAKCNH2 | |
| SCHEMBL19329276 | 0.88 | ATM (0.84) | ATMATRMTORPIK3CAKCNH2 | |
| SCHEMBL19329284 | 0.88 | ATM (0.79) | ATMATRMTORPIK3CAKCNH2 | |
| SCHEMBL19329285 | 0.88 | ATM (0.79) | ATMATRMTORPIK3CAKCNH2 | |
| SCHEMBL17242470 | 0.86 | ATM (0.76) | ATMATRMTORPIK3CAKCNH2 | |
| SCHEMBL17245537 | 0.86 | ATM (0.76) | ATMATRMTORPIK3CAKCNH2 | |
| SCHEMBL17246640 | 0.86 | ATM (0.76) | ATMATRMTORPIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017153578-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | WO | claimed |
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-08-17 | — | — | US | disclosed |
| WO-2017153578-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153578-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ATM, CHEK2, ERBB2 | ATM 1/4885ATR 7/4885MTOR 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.